Thomas Son

Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2 R,3 R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist

Kimberly E. Vanover, David M. Weiner, Malath Makhay et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 196 citations · Full text

Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7-H3 for Solid Cancer

Juniper A. Scribner, Jennifer G. Brown, Thomas Son et al. · Molecular Cancer Therapeutics · 2020 · 148 citations

AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

Stefania Risso Bradley, Jelveh Lameh, Linda Ohrmund et al. · Neuropharmacology · 2009 · 67 citations

Molecular Pharmacology, Cognitive Performance, Functional Selectivity +11

Pharmacological Characterization of AC-90179 [2-(4-Methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide Hydrochloride]: A Selective Serotonin 2A Receptor Inverse Agonist

Kimberly E. Vanover, Scott C. Harvey, Thomas Son et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 27 citations · Full text

Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator

Fabrice Piu, Luis R. Gardell, Thomas Son et al. · The Journal of Steroid Biochemistry and Molecular Biology · 2007 · 26 citations

Molecular Pharmacology, Pharmacological Characterization, Biochemistry +8